# Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

> **NCT03875859** · PHASE2 · TERMINATED · sponsor: **Kavita Sarin** · enrollment: 4 (actual)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Remetinostat

## Key facts

- **NCT ID:** NCT03875859
- **Lead sponsor:** Kavita Sarin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-12
- **Primary completion:** 2020-05-14
- **Final completion:** 2021-01-30
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The available study medication reached expiry (logistics).
- **Last updated:** 2021-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03875859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03875859, "Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03875859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*